Phosphorylation: Implications in Cancer

Overview

Journal Protein J

Publisher Springer

Specialty Biochemistry

Date 2017 Jan 22

PMID 28108801

Citations 127

Authors

Vishakha Singh

Mahendra Ram

Rajesh Kumar

Raju Prasad

Birendra Kumar Roy

Kaushal Kumar Singh

Affiliations

Soon will be listed here.

Abstract

Post translational modifications (PTMs) are involved in variety of cellular activities and phosphorylation is one of the most extensively studied PTM, which regulates a number of cellular functions like cell growth, differentiation, apoptosis and cell signaling in healthy condition. However, alterations in phosphorylation pathways result in serious outcomes in the form of diseases, especially cancer. Many signalling pathways including Tyrosine kinase, MAP kinase, Cadherin-catenin complex, Cyclin-dependent kinase etc. are major players of the cell cycle and deregulation in their phosphorylation-dephosphorylation cascade has been shown to be manifested in the form of various types of cancers. Tyrosine kinase family encompasses the greatest number of oncoproteins. MAPK cascade has an importance role in cancer growth and progression. Bcl-2 family proteins serve either proapoptotic or antiapoptotic function. Cadherin-catenin complex regulates cell adhesion properties and cyclins are the key regulators of cell cycle. Altered phosphorylations in any of the above pathways are strongly associated with cancer, at the same time they serve as the potential tergets for drug development against cancer. Drugs targeting tyrosine kinase are potent anticancer drugs. Inhibitors of MEK, PI3K and ERK signalling pathways are undergoing clinical trials. Thus, drugs targeting phosphorylation pathways represent a promising area for cancer therapy.

Citing Articles

Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy.

Hu Q, Shi Y, Wang H, Bing L, Xu Z Exp Hematol Oncol. 2025; 14(1):37.

PMID: 40087690 DOI: 10.1186/s40164-025-00627-6.

Proteomic and phosphoproteomic signatures of aging mouse liver.

Mohallem R, Schaser A, Aryal U Geroscience. 2025; .

PMID: 40087212 DOI: 10.1007/s11357-025-01601-0.

Characterization and chemoproteomic profiling of protein O-GlcNAcylation in SOD1-G93A mouse model.

Hao Y, Li Z, Du X, Xie Q, Li D, Lei S Mol Med. 2025; 31(1):82.

PMID: 40021952 PMC: 11871760. DOI: 10.1186/s10020-025-01134-4.

Implication of protein post translational modifications in gastric cancer.

Song H, Zhang M, Guo C, Guo X, Ma Y, Ma Y Front Cell Dev Biol. 2025; 13:1523958.

PMID: 39968176 PMC: 11833226. DOI: 10.3389/fcell.2025.1523958.

TMEM160 Promotes Tumor Growth in Lung Adenocarcinoma and Cervical Adenocarcinoma Cell Lines.

Herrera-Quiterio G, Valencia-Gonzalez H, de la Cruz-Lopez K, Fernandez-Coto D, Gil J, Marko-Varga G Int J Mol Sci. 2025; 26(3).

PMID: 39940865 PMC: 11816668. DOI: 10.3390/ijms26031097.

References

Yap A . The morphogenetic role of cadherin cell adhesion molecules in human cancer: a thematic review. Cancer Invest. 1998; 16(4):252-61. DOI: 10.3109/07357909809039774. View

Neshat M, Mellinghoff I, Tran C, Stiles B, Thomas G, Petersen R . Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A. 2001; 98(18):10314-9. PMC: 56958. DOI: 10.1073/pnas.171076798. View

Cohen P . The regulation of protein function by multisite phosphorylation--a 25 year update. Trends Biochem Sci. 2000; 25(12):596-601. DOI: 10.1016/s0968-0004(00)01712-6. View

Karin M, Ben-Neriah Y . Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000; 18:621-63. DOI: 10.1146/annurev.immunol.18.1.621. View

Cohen P . The origins of protein phosphorylation. Nat Cell Biol. 2002; 4(5):E127-30. DOI: 10.1038/ncb0502-e127. View

Jaggi M, Rao P, Smith D, Hemstreet G, Balaji K . Protein kinase C mu is down-regulated in androgen-independent prostate cancer. Biochem Biophys Res Commun. 2003; 307(2):254-60. DOI: 10.1016/s0006-291x(03)01161-6. View

Devin A, Cook A, Lin Y, Rodriguez Y, Kelliher M, Liu Z . The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity. 2000; 12(4):419-29. DOI: 10.1016/s1074-7613(00)80194-6. View

Radivojac P, Baenziger P, Kann M, Mort M, Hahn M, Mooney S . Gain and loss of phosphorylation sites in human cancer. Bioinformatics. 2008; 24(16):i241-7. PMC: 2732209. DOI: 10.1093/bioinformatics/btn267. View

Nakanishi C, Toi M . Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005; 5(4):297-309. DOI: 10.1038/nrc1588. View

10.

Lilien J, Balsamo J, Arregui C, Xu G . Turn-off, drop-out: functional state switching of cadherins. Dev Dyn. 2002; 224(1):18-29. DOI: 10.1002/dvdy.10087. View

11.

Loughrey Chen S, Huddleston M, Shou W, Deshaies R, Annan R, Carr S . Mass spectrometry-based methods for phosphorylation site mapping of hyperphosphorylated proteins applied to Net1, a regulator of exit from mitosis in yeast. Mol Cell Proteomics. 2002; 1(3):186-96. DOI: 10.1074/mcp.m100032-mcp200. View

12.

Ahmad I, Hoessli D, Walker-Nasir E, Choudhary M, Rafik S, Shakoori A . Phosphorylation and glycosylation interplay: protein modifications at hydroxy amino acids and prediction of signaling functions of the human beta3 integrin family. J Cell Biochem. 2006; 99(3):706-18. DOI: 10.1002/jcb.20814. View

13.

Burnett G, Kennedy E . The enzymatic phosphorylation of proteins. J Biol Chem. 1954; 211(2):969-80. View

14.

Benson J, Chen Y, Cornell-Kennon S, Dorsch M, Kim S, Leszczyniecka M . Validating cancer drug targets. Nature. 2006; 441(7092):451-6. DOI: 10.1038/nature04873. View

15.

Hunter T . Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell. 1995; 80(2):225-36. DOI: 10.1016/0092-8674(95)90405-0. View

16.

Avizienyte E, Wyke A, Jones R, McLean G, Westhoff M, Brunton V . Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat Cell Biol. 2002; 4(8):632-8. DOI: 10.1038/ncb829. View

17.

Tergaonkar V, Bottero V, Ikawa M, Li Q, Verma I . IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy. Mol Cell Biol. 2003; 23(22):8070-83. PMC: 262380. DOI: 10.1128/MCB.23.22.8070-8083.2003. View

18.

Nahta R, Yuan L, Du Y, Esteva F . Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther. 2007; 6(2):667-74. DOI: 10.1158/1535-7163.MCT-06-0423. View

19.

Zuo L, Weger J, Yang Q, Goldstein A, Tucker M, Walker G . Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 1996; 12(1):97-9. DOI: 10.1038/ng0196-97. View

20.

Lickert H, Bauer A, Kemler R, Stappert J . Casein kinase II phosphorylation of E-cadherin increases E-cadherin/beta-catenin interaction and strengthens cell-cell adhesion. J Biol Chem. 2000; 275(7):5090-5. DOI: 10.1074/jbc.275.7.5090. View